Boston, MA -- (SBWIRE) -- 08/06/2013 -- Progenra, Inc. (Progenra) is a biotechnology company. The company discovers and develops therapeutic medicines. Its products under clinical development include P005091, P013222, and P009492. Progenra's products are used in the areas of oncology, muscle wasting, central nervous system, lipid metabolism, and inflammation. The company develops products of various compounds, which modulate DUB and E3 ligase activities. Its DUB technology platform utilizes substrate specific assays to identify selective small molecule inhibitors of DUBs. The company also develops ligase technology platform that receives ubiquitin from an E2 enzyme and transfers it to the target protein. It partners with Tokyo medical University. Progenra is headquartered in Malvern, Pennsylvania, the US.

View Full Report Details and Table of Contents

This report is a source for data, analysis and actionable intelligence on the Progenra, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Get This Report

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Medical Devices research reports at Fast Market Research

You may also be interested in these related reports:

- GE Healthcare - Product Pipeline Analysis , 2013 Update
- Philips Healthcare - Product Pipeline Analysis, 2013 Update
- Boston Scientific Corporation (BSX) - Product Pipeline Analysis, 2013 Update
- St. Jude Medical, Inc. (STJ) - Product Pipeline Analysis, 2013 Update
- Siemens Healthcare - Product Pipeline Analysis, 2013 Update
- Cepheid (CPHD) - Product Pipeline Analysis, 2013 Update
- Qiagen N.V. (QIA) - Product Pipeline Analysis, 2013 Update
- Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis, 2013 Update
- VentriPoint, Inc. - Product Pipeline Analysis, 2013 Update
- Teleflex Incorporated (TFX) - Product Pipeline Analysis, 2013 Update